SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Meeks J. J.)
 

Sökning: WFRF:(Meeks J. J.) > Tumor Subtyping : M...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00003839naa a2200409 4500
001oai:lup.lub.lu.se:f4868346-de57-40ce-a744-ff4df1e1342a
003SwePub
008210409s2021 | |||||||||||000 ||eng|
024a https://lup.lub.lu.se/record/f4868346-de57-40ce-a744-ff4df1e1342a2 URI
024a https://doi.org/10.3233/BLC-2003062 DOI
040 a (SwePub)lu
041 a engb eng
042 9 SwePub
072 7a for2 swepub-publicationtype
072 7a ref2 swepub-contenttype
100a Meeks, Joshua J.u Northwestern University,Jesse Brown VA Medical Center4 aut
2451 0a Tumor Subtyping : Making Sense of Heterogeneity with a Goal Toward Treatment
264 1c 2021
300 a 11 s.
520 a BACKGROUND: Bladder cancers have high total mutation burdens resulting in genomic diversity and intra-and inter-tumor heterogeneity that may impact the diversity of gene expression, biologic aggressiveness, and potentially response to therapy. To compare bladder cancers among patients, an organizational structure is necessary that describes the tumor at the histologic and molecular level. These 'molecular subtypes', or 'expression subtypes' of bladder cancer were originally described in 2010 and continue to evolve secondary to next generation sequencing (NGS) and an increasing public repository of well-annotated cohorts. OBJECTIVE: To review the history and methodology of expression-based subtyping of non-muscle invasive (NMIBC) and muscle invasive bladder cancer (MIBC). METHODS: A literature review was performed of primary papers from PubMed that described subtyping methods and their descriptive feature including search terms of 'subtype', and 'bladder cancer'. RESULTS: 21 papers were identified for review. Tumor subtyping developed from N = 2 to N = 6 subtyping schemes with most subtypes comprised of at least luminal and basal tumors. Most NMIBCs are luminal cancers and luminal MIBCs may be associated with less aggressive features, while one study of basal tumors identified a better clinical outcome with systemic chemotherapy. Tumors with a P53-like may have intrinsic resistance to chemotherapy. The heterogeneity of tumors, which is likely derived from stromal components and immune cell infiltration, affect subtype calls. CONCLUSION: Subtyping, while still evolving, is ready for testing in clinical trials. Improved patient selection with tumor subtyping may help with tumor classification and potentially match patient or tumor to therapy.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
653 a Bladder cancer
653 a expression-based subtyping
653 a immunology
653 a stroma
653 a systemic therapy
700a Sjödahl, Gottfridu Lund University,Lunds universitet,Genomiska analyser av urinblåscancer,Forskargrupper vid Lunds universitet,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Urothelial Cancer Genomics,Lund University Research Groups,LUCC: Lund University Cancer Centre,Other Strong Research Environments4 aut0 (Swepub:lu)med-gsj
700a Lerner, Seth P.u Baylor College of Medicine4 aut
700a Das, Arighnou University of Wisconsin-Madison4 aut
700a McConkey, David J.u Johns Hopkins University4 aut
700a Black, Peter C.u University of British Columbia4 aut
710a Northwestern Universityb Jesse Brown VA Medical Center4 org
773t Bladder Cancerg 7:1, s. 1-11q 7:1<1-11x 2352-3727
856u http://dx.doi.org/10.3233/BLC-200306x freey FULLTEXT
8564 8u https://lup.lub.lu.se/record/f4868346-de57-40ce-a744-ff4df1e1342a
8564 8u https://doi.org/10.3233/BLC-200306

Hitta via bibliotek

Till lärosätets databas

Sök utanför SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy